Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4482 - Functional inhibition of TGF-_ in colorectal cancer cells and its interaction with AXL receptor

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Davide Ciardiello

Citation

Annals of Oncology (2018) 29 (suppl_8): viii1-viii13. 10.1093/annonc/mdy268

Authors

D. Ciardiello1, G. Martini2, N. Matrone1, V. Belli1, P.P. Vitiello1, C. Cardone1, V. Ciaramella1, G. Barra3, L. Poliero1, C. Borrelli4, T. Troiani1, D. Melisi5, F. Morgillo1, E.F. Giunta1, V. De Falco1, F. Ciardiello1, E. Martinelli1

Author affiliations

  • 1 Medicina Di Precisione, Università degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
  • 2 Centro Cellex, Vall D'Hebron institute of oncology (VHIO), 08035 - Barcelona/ES
  • 3 Medicina Di Precisione, Università degli Studi della Campania Luigi Vanvitelli, 80138 - Napoli/IT
  • 4 Medicina Di Precisione, Università degli Studi della Campania Luigi Vanvitelli, 81100 - Napoli/IT
  • 5 Medicina, AOU Integrata Verona "Borgo Roma", 37134 - Verona/IT
More

Resources

Abstract 4482

Background

AXL and transforming growth factor β (TGF-β) are correlated with epithelial to mesenchymal transition, invasiveness, angiogenesis and immune modulation in colorectal cancer (CRC). We have previously demonstrated that targeting AXL caused a significant blockade of cancer cell proliferation and migration. Here we have evaluated the role of TGF-β signalling and the potential interaction between TGF- β and AXL in human CRC cell lines.

Methods

We assessed the expression and activation of TGF-β and AXL in a panel of human CRC cell lines (HCT116, SW480, LOVO, LIM 1215 and SW48) by Western Blot (WB) and Real time PCR. We tested the sensitivity of Galunisertib (LY21209761), a TGF-β R1 inhibitor, in HCT116 and LOVO cells the treatment by using MTT, soft-agar colony forming, cell invasion and wound healing assays. To study the correlation between these two pathways, we generated stable LOVO short hairpin RNA (shRNA)-sh-AXL cells clones, in which AXL expression was decreased, and stimulated both parental and shAXL LOVO cells with TGF-β1.

Results

TGF-β receptors 1 and 2 were expressed in all cell lines, whereas AXL was expressed only in HCT116, SW480, LOVO cells. Treatment with Galunisertib had a modest effect on cancer cell growth, whereas it significantly decreased TGF-β induced cell migration, invasion and colony formation in HCT116 and LOVO cells (that co-expressed both TGF-β receptors and AXL). The stimulation of HCT116 and LOVO cells with TGF-β1 resulted in increased levels of phosphorylated (p) AXL, pAKT, and p38 MAPK proteins. However, in contrast to parental LOVO cells, no increase in p38 MAPK was found in LOVO shAXL clones, upon TGF-β stimulation.

Conclusions

In HCT116 and LOVO cells, TGF-β mediated cell migration, invasion and soft agar colony growth formation were significantly inhibited by Galunisertib treatment. Furthermore, a functional potential cross talk between TGF-β induced signalling and AXL could converge on p38 MAPK activation. In this respect, combined treatments with Galunisertib and AXL inhibitors are ongoing to evaluate their antitumor effects in CRC cells.

Clinical trial identification

Legal entity responsible for the study

Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli.

Funding

AIRC (Associazione Italiana per la Ricerca sul Cancro) MFAG-2015-ID:7778.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings